Shots:
What started as a father’s determination to find a better solution has grown into a widely reimbursed therapy. Along the way, strong clinical evidence, early physician support, and carefully designed payer pilots helped unlock nationwide coverage, reaching nearly 130 million lives across Blue Cross Blue Shield plans.
In this conversation, Alon explains how Nerivio’s dual acute and preventive…
Shots:
Lundbeck has reported P-IIb (PROCEED) trial results evaluating bocunebart (SC/IV; QM for 3mos.) vs PBO in migraine patients with prior failure of 1-4 preventive therapies, with the IV arm randomizing 431 pts across 14 countries
Trial met its 1EP in the multiple IV dosing arm, showing a statistically significant reduction in monthly migraine days…

